Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 6,025 Shares

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 6,025 shares of Genelux stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $3.67, for a total value of $22,111.75. Following the completion of the transaction, the insider now owns 1,189,706 shares of the company’s stock, valued at $4,366,221.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, May 1st, Aladar Szalay sold 33,061 shares of Genelux stock. The shares were sold at an average price of $3.30, for a total transaction of $109,101.30.
• On Monday, April 29th, Aladar Szalay sold 6,403 shares of Genelux stock. The stock was sold at an average price of $3.25, for a total value of $20,809.75.
• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total value of $28,224.00.
• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Trading Down 6.2 %

GNLX traded down $0.25 during trading on Friday, reaching $3.77. The company had a trading volume of 40,888 shares, compared to its average volume of 123,528. The firm’s 50-day simple moving average is $4.97 and its 200 day simple moving average is $9.70. Genelux Co. has a 12-month low of $3.06 and a 12-month high of $40.98.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Analysts expect that Genelux Co. will post -0.81 earnings per share for the current year.

Hedge Funds Weigh In On Genelux

A number of hedge funds have recently modified their holdings of the stock. Amalgamated Bank grew its stake in shares of Genelux by 250.8% in the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock valued at $26,000 after buying an additional 770 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Genelux by 216.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock worth $41,000 after acquiring an additional 2,021 shares in the last quarter. Barclays PLC grew its position in Genelux by 516.4% in the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock worth $83,000 after acquiring an additional 2,835 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Genelux by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock worth $87,000 after purchasing an additional 1,573 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of Genelux by 17.6% in the 4th quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock valued at $91,000 after purchasing an additional 966 shares during the last quarter. 37.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GNLX has been the subject of a number of research analyst reports. Benchmark reissued a “speculative buy” rating and issued a $30.00 price target on shares of Genelux in a report on Wednesday, April 3rd. HC Wainwright reduced their target price on shares of Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.